Basics Madrigal Pharmaceuticals, Inc. Madrigal Pharmaceuticals Inc is a company focused on the development of novel compounds for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). IPO Date: February 6, 2007 Sector: Healthcare Industry: Biotech Market Cap: $9.65B Activated in VL: True Average Daily Range Avg Daily Range: $3.62 | 2.58% Avg Daily Range (30 D): $6.89 | 1.94% Avg Daily Range (90 D): $6.13 | 1.92% Institutional Daily Volume Avg Daily Volume: .21M Avg Daily Volume (30 D): .35M Avg Daily Volume (90 D): .29M Trade Size Avg Trade Size (Sh.): 44 Avg Trade Size (Sh.) (30 D): 30 Avg Trade Size (Sh.) (90 D): 30 Institutional Trades Total Inst.Trades: 2,288 Avg Inst. Trade: $5.86M Avg Inst. Trade (30 D): $12.49M Avg Inst. Trade (90 D): $10.81M Avg Inst. Trade Volume: .03M Avg Inst. Trades (Per Day): 1 Market Closing Trades Avg Closing Trade: $6.25M Avg Closing Trade (30 D): $13.3M Avg Closing Trade (90 D): $12.27M Avg Closing Volume: 32.5K     News Aug 5, 2025 @ 8:07 PM Madrigal (MDGL) Q2 Revenue Soars 1,313% Source: Na Jul 25, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release Second-Quarter... Source: Madrigal Pharmaceuticals May 10, 2025 @ 11:15 AM Madrigal Announces New Clinical Data Demonstrating... Source: N/A Apr 18, 2025 @ 12:00 PM Madrigal Pharmaceuticals to Release First-Quarter ... Source: N/A Feb 26, 2025 @ 5:28 PM Madrigal Pharmaceuticals Stock Jumps On New Two-Ye... Source: Vandana Singh Financials   TTM Q2 2025 Q1 2025 Basic EPS $-12.73 $-1.9 $-3.32 Diluted EPS $-12.73 $-1.9 $-3.32 Revenue $ 515.55M $ 212.8M $ 137.25M Gross Profit $ $ $ 132.74M Net Income / Loss $ -281.9M $ -42.28M $ -73.24M Operating Income / Loss $ -309.81M $ -47.2M $ -79.31M Cost of Revenue $ $ $ 4.51M Net Cash Flow $ -308.4M $ 2.55M $ 83.63M PE Ratio     Splits Jul 25, 2016:   1:35